A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

NCT06769412 · clinicaltrials.gov ↗
COMPLETED
Status
550000
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Regeneron Pharmaceuticals